Patient group
Erwachsene mit generalisierter Myasthenia gravis, die Anti-Acetylcholin-Rezeptor -Antikörper positiv sind
completed2022-09-01D series
Efgartigimod alfa
Myasthenia gravis, AChR-Antikörper+
Open official case page ↗
- Brand
- Vyvgart
- Manufacturer
- Argenx Germany GmbH
G-BA action
final resolution
2023-02-16
Arzneimittel-Richtlinie/Anlage XII: Efgartigimod alfa (Myasthenia gravis, AChR-Antikörper+)
Evidence-checked summary
The G-BA found a hint of considerable added benefit for Erwachsene mit generalisierter Myasthenia gravis, die Anti-Acetylcholin-Rezeptor -Antikörper positiv sind. The G-BA issued a final resolution on 2023-02-16. The official page states that it took effect as follows: aufgehoben. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Final benefit result
G-BA result by patient group
Official case record
What happened, in source order
No inferred stages
Consultation record
Oral hearing and Wortprotokoll
2023-01-09
100 parsed turns
Oral hearing: Efgartigimod alfa (Myasthenia gravis, AChR-Antikörper+)
Official Wortprotokoll · 15 pages
IQWiG comparison
Assessment record versus G-BA action
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
No IQWiG assessment reference is present on the validated official case page. This is an explicit absence, not a broken graph link.
G-BA decisions
Distinct actions and documents
2023-02-16
final resolution
Arzneimittel-Richtlinie/Anlage XII: Efgartigimod alfa (Myasthenia gravis, AChR-Antikörper+)
The G-BA found a hint of considerable added benefit for Erwachsene mit generalisierter Myasthenia gravis, die Anti-Acetylcholin-Rezeptor -Antikörper positiv sind. The G-BA issued a final resolution on 2023-02-16. The official page states that it took effect as follows: aufgehoben. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
3 official documents · 4 cited claims
Official sources
Case document package
official case pageOfficial G-BA case pageOpen ↗gba assessment amendmentAmendment zur Nutzenbewertung des G-BAOpen ↗iqwig cost assessmentBewertung der Therapiekosten und Patientenzahlen IQWiGOpen ↗gba assessmentNutzenbewertung G-BAOpen ↗hearing transcriptWortprotokollOpen ↗decision textBeschlusstextOpen ↗decision rationaleTragende Gründe zum BeschlussOpen ↗summary documentationZusammenfassende DokumentationOpen ↗
Generic graph relations · 5
HAS ASSOCIATED DECISIONArzneimittel-Richtlinie/Anlage XII: Efgartigimod alfa (Myasthenia gravis, AChR-Antikörper+)HAS HEARINGOral hearing: Efgartigimod alfa (Myasthenia gravis, AChR-Antikörper+)OWNS DOCUMENTAmendment zur Nutzenbewertung des G-BAOWNS DOCUMENTBewertung der Therapiekosten und Patientenzahlen IQWiGOWNS DOCUMENTNutzenbewertung G-BA